# OnCo record envafolimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/envafolimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "envafolimab" ;
  schema:name "Envafolimab"@en ;
  schema:description "Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency."@en ;
  schema:url <https://onco.cc/drugs/envafolimab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Envafolimab> ;
  schema:citation <https://www.alphamabonc.com/en/>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Single-domain antibody (anti-PD-L1, subcutaneous)" ;
  schema:alternateName "Enweida" ;
  onco:approval "China 2021: Previously treated MSI-H or dMMR advanced solid tumours" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/cancer-of-unknown-primary/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/alphamab/>, <https://onco.cc/companies/3d-medicines/>, <https://onco.cc/companies/tracon/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/msi/> ;
  onco:trials <https://onco.cc/trials/nct05112991/>, <https://onco.cc/trials/nct05024214/>, <https://onco.cc/trials/nct04891198/>, <https://onco.cc/trials/nct03478488/>, <https://onco.cc/trials/nct03667170/>, <https://onco.cc/trials/nct06123754/> .